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http:WHAT THIS PAPER ADDS
This retrospective study describes the economic and clinical impact of diabetes mellitus as a comorbid variable
in patients with peripheral arterial disease undergoing lower limb vascular intervention. Few reports from within
Australia present the costs of patients with lower limb pathology requiring procedures such as amputation, open
bypass, and angioplasty. This paper reﬂects the impact of diabetes in two major ways: length of stay in hospital
and inpatient costs. Each patient journey was mapped individually and all results crosschecked between paper
charts, electronic medical records, coding records, and the vascular audit database, capturing an accurate
reﬂection of inpatient costs. The study adds to existing literature and provides one of only a few reports of
vascular surgery costs and length of stay from an Australian perspective.Objective: To determine the impact of diabetes mellitus (DM) and other comorbidities on length of stay (LOS)
and costs in patients with peripheral arterial disease (PAD) admitted to a vascular surgical unit.
Methods: A retrospective study was conducted between January 2011 and July 2012 at a tertiary referral hospital
in Sydney. Demographic, laboratory, and operative data were obtained from the Australasian Vascular Audit
database and hospital diagnostic-related group (DRG) reports. Patients with conﬁrmed PAD with or without DM
requiring hospital admission for a diagnosis of claudication, rest pain, ulcer/gangrene, and infection that required
lower limb surgical intervention were included. Associations between LOS, surgical procedure, and DRG were
explored.
Results: Five hundred and sixty-eight admissions (492 patients) were identiﬁed: 292 admissions with PAD and
276 admissions with PAD in conjunction with DM (PADDM). Mean LOS for patients with PAD was 10  13.7 days
compared with 15  18.2 days for PADDM (p < .01; 95% conﬁdence interval 2.7e8.0). LOS and costs were
greatest in patients with PADDM undergoing major amputation (37  13.7 days; US$42,236; p < .01). Analysis of
variance indicated that the best predictors of LOS were the presence of DM, bypass surgery, amputation, chronic
kidney disease (CKD) stage V, infection, and emergency admission. Over 18 months, the estimated total inpatient
costs associated with lower limb intervention for PAD with and without DM amounted to US$7,598,597. People
with DM incurred greater inpatient costs, averaging US$1,912 more per episode of admission and a total of
US$528,029 over 18 months.
Conclusion: The impact of diabetes as a comorbid condition in patients with PAD is signiﬁcant, both clinically and
economically. Factors that predict increased LOS in patients with PAD are DM, bypass surgery, amputation, CKD
stage V, infection, and emergency admission.
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From a health economic perspective, the treatment of pe-
ripheral arterial disease (PAD) is costly owing to the need
for invasive investigations, hospitalization, and surgery.1 The
prevalence of PAD varies depending on the deﬁning criteria
and age of the study population, with the age-standardized
prevalence estimated at 2e6% for the general popula-
tion.2e5 Managing PAD in combination with comorbidities
448 M. Malone et al.such as diabetes mellitus (DM), hypertension (HTN), and
hyperlipidemia complicates the expense.6 To date, there
have been no Australian-based studies that have examined
the cost of patients with PAD (with or without DM) who
require admission and lower limb surgical procedures in a
vascular surgery ward. The available research has predom-
inantly been conducted in North American healthcare sys-
tems, which are not directly comparable with Australian
healthcare systems. Data from European countries that are
more reﬂective of an Australian perspective, in particular
the UK, have provided the closest reﬂection of the problem
at large. In one such study by Currie et al., where the cost of
inpatient care in people with peripheral vascular disease
and foot complications was reported, diagnostic-related
group (DRG) codes were utilized to estimate that, over a
4-year period, admissions cost a total of US$9,743,855.
The aim of this study was to determine the cost and
length of stay (LOS) in inpatients with PAD undergoing
vascular surgical procedures on a lower limb, with a
particular focus from an Australian health perspective and
the impact of DM as a comorbid variable.METHODS
Between 1 January 2011 and 7 July 2012 a retrospective
cohort analysis was conducted at a tertiary referral hospital in
metropolitan Sydney (Liverpool Hospital, NSW, Australia).
Patient demographics were obtained through clinical records
and hospital laboratory data, and surgical procedure reports
were obtained from the Australian and New Zealand Society
for Vascular Surgery’s Australasian Vascular Audit database
(AVU) for patients with a conﬁrmed diagnosis of PADwith and
without DM who underwent any form of vascular surgical
intervention,7 including surgeon-performed angiography. The
data inputted into the AVU were collected prospectively;
however, data for the study were analyzed retrospectively.
Only patients undergoing lower limb interventions were
included in the dataset. All surgical procedures andTable 1. Peripheral arterial disease (PAD) and PAD with diabetes mellitu
Australian-reﬁned DRG coding system mapping of individual patient a
intervention group.
Intervention PAD cost average per
patient mapped individually
PAD
(group
Minor amputation 21,849a 196,
Major amputation 40,195a 643,
Open bypass 24,727a 667,
PTA 11,072a 1,699,
Debridement 14,209a 85,
Average total cost 22,410b 3,320,
Additional average
cost per patient admission
Additional treatment costs
Note. PTA ¼ percutaneous angioplasty.
a Average cost per patient.
b Total average cost per admission regardless of intervention type.
c Average additional cost of PADDM per admission against those with
d Total average additional costs incurred for all admissions of PADDMinterventional radiographic procedures during the admis-
sion for a patient in this sample were undertaken by
vascular surgeons. More than one admission might occur
for a patient during the study period, and more than one
procedure might be performed on a patient during an
admission.
DM was conﬁrmed through medical records using current
diagnostic guidelines.8 Glycemic control was identiﬁed using
glycosylated hemoglobin (HbA1c) readings. Suboptimal
glycemic control was deﬁned as an HbA1c >7%.9 Chronic
kidney disease (CKD) was deﬁned using estimated glomer-
ular ﬁltration guidelines.10
Amputations were deﬁned to match the Australian-
reﬁned DRG coding system (AR-DRG),11 with major ampu-
tations classiﬁed as an amputation for circulatory system
disorders except the upper limb and toe, and minor am-
putations classiﬁed as upper limb and toe amputations for
circulatory system disorders. No upper limb amputation
patients were included in the amputation dataset. The
clinical diagnosis of infection was based on the Infectious
Disease Society of America guidelines for diabetic foot in-
fections,12 in addition to laboratory and imaging results.Calculating the associated inpatient costs utilizing clinical
coding
Associated inpatient costs were calculated utilizing AR-DRG
codes to assign the matching standard New South Wales
public hospital cost weight.11 All values are shown in US$.
For each patient, admission and discharge date, principal
diagnosis, principal procedure, and comorbidities were
extracted and crosschecked between paper and electronic
records. The cost of each patient’s episode of admission was
individually calculated.
The cost for multiple procedures during a single admis-
sion was not calculated. Each admission was costed against
the highest surgical procedure undertaken. The chief driver
of cost in the AR-DRG system is LOS. Therefore, if a patients (PADDM) ﬁgures are quoted in US$. Inpatient costs are based on
dmissions to provide approximate costs for all patients within an
totals)
PADDM average per
patient mapped
individually
PADDM
(group totals)
Total cost
649 27,068a 1,326,377 1,523,026
137 42,236a 886,979 1,538,543
631 20,099a 341,701 943,788
266 13,853a 1,579,310 3,306,667
257 18,022a 144,187 229,445
033 24,256b 4,278,555 7,598,597
1,912c
528,029d
PAD only.
then those with PAD only over the 18-month study duration.
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of procedure was based on the highest procedure under-
taken (amputation). For cost calculations, patients with
private health insurance were treated the same as state-
funded patients.Statistical analysis
Statistical analysis was performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA). Unpaired t tests and chi-
square tests with and without risk ratio were employed in
testing for differences between the cohorts. Censoring of
outliers was performed. Analysis of variance (general linear
model [GLM]) was used to explore the association between
selected variables. For all comparisons and modeling, the
level of signiﬁcance was set at p < .05. Data are given as
mean  SD.
RESULTS
Five hundred and sixty-eight admissions were identiﬁed for
492 patients, of which 181 admissions were women (32%)
with a mean age 69.0  13.9 years; 387 admissions were
men (68%) with a mean age 70.0  12.0 years. The cohort
was divided into patients with PAD alone (PAD) or PAD and
DM (PADDM). Of the 568 admissions, 292 had PAD alone
and 276 had PADDM. There was no signiﬁcant difference
between the age and sex of the patients in the PAD and
PADDM groups. The mean LOS for patients with PAD was
10  13.7 days compared with 15  18.2 days for patients
with PADDM (p < .01; 95% conﬁdence interval [CI] 2.70e
8.00).
During the study period, 711 surgical procedures were
undertaken for the following procedures: amputation,
percutaneous transluminal angioplasty (PTA), open bypass,
and wound debridement. Over an 18-month period, the
cost of the inpatient stay of the total group was $7,598,597
(Table 1).HTN
The total number of patients with HTN in this study was
high (93%), but there was no difference in prevalence be-
tween groups (PAD 46%, PDDM 46%).Presence of infection
In admissions for infection in patients with PADDM, LOS
increased by 5 days compared with admissions for infection
in patients with PAD alone (PAD 10 days  13.8 days vs.
PADDM 15 days  18 days; p < .01; 95% CI 7.97 to 2.71).
Regardless of comorbidity, admissions with infection spent
13.0  16.1 days longer in hospital than those without
infection (p < .01; 95% CI 9.30e15.60).
Of admissions with PADDM, 225/276 (82%) had
infection at or during the time of their admission
compared with 102/292 (35%) with PAD. Patients with
PADDM were 3.3 times more likely to have an infection
than patients with PAD alone (risk ratio [RR] 95% CI
2.50e4.20).Emergency versus elective (planned) admission
Patients admitted as emergency cases spent 6 days longer
in hospital than those admitted as elective cases (PAD 10
days  13.1 days vs. PADDM 16 days  18.5 days; p < .01,
95% CI e9.48 to 4.16).Amputation
Patients with PADDM were three times more likely to have
an amputation compared with those with PAD alone (RR
2.9; 95% CI 1.90e4.30). Hospital LOS and cost were
greatest in patients undergoing major amputation (PAD 35
days  27.6 days, $40,195; PADDM 37 days  15.3 days,
$42,236), with no signiﬁcant differences between the
groups (p ¼ .90; 95% CI e20.23 to 17.05). The inpatient
cost for admissions with major amputation over the study
period totalled $1,530,116 (PAD $643,187 vs. PADDM
$886,979).
Minor amputations also resulted in increased LOS in both
cohorts, although this was not signiﬁcant (PAD 19
days  15.3 days, $24,498; PADDM 18 days  17.8 days,
$25,190; p ¼ .70, 95% CI e9.47 to 13.78). Total inpatient-
associated costs for this group were $1,523,026 (PAD
$196,640 vs. PADDM $1,326,377). The total cost of inpa-
tient care attributable to lower extremity amputation was
$3,162,644.Revascularization
The lowest LOS was recorded for patients having endovas-
cular surgery. Patients with PAD undergoing PTA stayed 6
days  10.4 days in hospital (cost $11,072), while those
with PADDM requiring the same procedure spent signiﬁ-
cantly longer in hospital (10  12.4 days, cost $13,853;
p < .01; 95% CI e6.14 to 1.31).
Patients requiring lower limb revascularization utilizing
bypass surgery incurred longer LOSs for both PAD (15
days  13.6 days; cost $24,727) and PADDM (18
days  13.6 days; cost $20,099) but the difference was not
signiﬁcant (p ¼ .50; 95% CI e12.34 to 10.05). Patients un-
dergoing open bypass surgery spent signiﬁcantly longer in
hospitaldalmost double the length of time as those who
had PTA alone (PTA 8 days  11.5 days vs. open bypass 15
days  13.3 days; p < .01).Kidney disease
Thirty-two admissions (6%) had stage V CKD (deﬁned as an
eGFR <15), of which ﬁve a had PAD alone; 27 admissions
had PADDM. No signiﬁcance was found between the two
groups for LOS (17 days  13.7 days vs. 18  15.8 days;
p ¼ .90; 95% CI e17.39 to 16.78). In those with PADDM and
stage V CKD, the presence of stage V CKD was associated
with a signiﬁcantly increased LOS (18 days  15.8 days)
when compared to those with normal or mildly reduced
kidney function (CKD stages 1e2, eGFR >60; 11 days  14
days, 95% CI 0.68e11.73; p < .03). In those with stage V
CKD, 14 underwent amputation (44% of 32 admissions with
stage V CKD and 3% of a total 568 admissions), with 12 of
450 M. Malone et al.these amputations occurring in those with PADDM
(p < .01).
Glycemic control
The mean HbA1C for those with PADDM was 8.2%.
Predicting LOS using GLM
The general linear model (GLM) examined the dependent
variable of length of stay against independent variables. The
signiﬁcant results are given in Table 2. The independent
variables of age and sex were not indicators of increased
LOS, while those of infection, emergency admission,
amputation, bypass surgery, stage V CKD, and DM were
predictors for increased LOS. DM as a comorbidity, inde-
pendent of other variables, was a signiﬁcant predictor for
increased LOS (p < .01).
DISCUSSION
This retrospective cohort analysis estimates the costs and
LOS of inpatients with PAD with and without DM who
required lower limb surgical intervention by a vascular
surgeon. The analysis does not account for any out-of-
hospital healthcare costs or any indirect costs. As the to-
tal care of cost excludes procedures other than the major
procedure accounting for the LOS, the total cost of care
associated with a lower limb vascular procedure is likely to
be signiﬁcantly higher.
The methodology for costing used in this study is that
currently used to fund public hospitals in New South Wales,
Australia, and presents a realistic representation of inpa-
tient costs, even though estimated rather than directly
calculated from a dedicated costing study. In the analyses,
each patient’s admission was mapped utilizing AR-DRG
codes and New South Wales cost-weights. While the AR-
DRG coding system reﬂects the whole inpatient experi-
ence, and is periodically updated to match changes in
clinical practice, the accuracy of cost-weights can become
degraded over time, which is the major weakness in the
system. In this instance, health cost estimates account for
LOS (accommodation, pathology tests, drugs, imaging
costs), cost of procedures, clinical occasions of service, and
comorbid conditions (drugs, pathology costs, etc.) that
complicate medical care.
Research that relies on the AR-DRG clinical code system
to estimate healthcare costs has encountered signiﬁcantTable 2. Dependent variables associated with increased length of
stay (LOS) using general linear modeling.
Variable acting on LOS p
Amputation <.01
Bypass <.01
PADDM <.01
CKD stage V <.01
Infection <.01
Emergency admission <.01
Note. PADDM ¼ peripheral arterial disease with diabetes mellitus;
CKD ¼ chronic kidney disease.issues related to data integrity.13,14 Coding may be per-
formed by trained, nonmedical coders using discharge
summaries and clinical records, which are often incomplete
or poorly reﬂect all of a patient’s relevant diagnoses. In this
study, these problems were avoided by allocating AR-DRG
codes for each admission only after manually cross-
referencing all of the data from the AVU database against
the relevant paper and electronic medical records. Known
diagnoses in an admission are assigned by both trained
nonmedical coders and medical staff.
LOS may vary depending on the ability to transfer stable
patients who undergo major amputation from a tertiary
surgical bed into a rehabilitation unit or community setting
for prosthetic rehabilitation. Only patients not capable of
managing at home with walking aids and wheelchairs are
transferred for inpatient prosthetic rehabilitation at Liver-
pool Hospital. It is possible that the LOS was extended for
some patients while they were waiting for a rehabilitation
bed. The hospital is supported by high-risk foot clinics,
wound clinics, and a community nursing ofﬁce providing
domiciliary care of complex wounds, including V.A.C.
dressings (KCI Medical, Kidlington, UK). Patients were dis-
charged when their condition could be safely managed in
the community.
This study makes no distinction in analysis between
elective admissions and unplanned/emergency admissions.
The groups in this study are selected on the basis that the
patients underwent a vascular procedure on the lower limb
by a surgeon, and excludes those who were admitted to a
vascular surgical ward and who did not undergo a vascular
procedure. The reason for admission was not rigorously
subcategorized, as this would add unduly to the complexity
of the results without affecting the major conclusions. The
study includes multiple admissions and procedures for pa-
tients, as this does not affect the major conclusions
regarding total costs, which are predominantly driven by
bed-day cost estimates.
The ﬁndings are consistent with previous reports that pa-
tients with PAD, with or without DM, consume a large pro-
portion of hospital resources.15,16 In contrast to patients with
PAD, patients with PADDM spent nearly twice as long in
hospital (10 days vs. 15 days). This is in agreement with pre-
vious reports, with one particular study from the UK reporting
similar lengths of stay for patients without DM versus those
with DMwho were admitted with peripheral vascular disease
and diabetes foot disease (15.5 days vs. 8.7 days).17
The presence of DM added an average of $1912 per
admission. An HbA1c level >7% was associated with 9 days
longer in hospital than for patients without DM, a ﬁnding
consistent with current reporting.15e19 The major factor
explaining the effect of diabetes on LOS and therefore costs
is the presence of infection in patients with diabetes. For
patients with PADDM, prevention of infection may reduce
LOS and perhaps improve hospital outcomes. With the old
adage that “prevention is better than cure”, increased uti-
lization of specialist multidisciplinary high-risk foot clinics
may decrease PADDM-related admissions and thus lower
the burden that PADDM places on the healthcare system.
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group. Patients with PADDM were three times more likely
to undergo amputation than patients with PAD alone.
Similar reports on amputation risks in people with PADDM
have been reported by Jude et al.,20 who studied diabetic
and nondiabetic patients undergoing arteriography and
concluded that patients with PADDM were ﬁve times more
likely to undergo amputation then people with PAD alone.
Endovascular surgery for the lower extremity improves
limb salvage rates when utilized as a ﬁrst-line approach,21
with limb salvage rates comparable with those from open
bypass surgery. The most common form of surgery under-
taken in this study was endovascular intervention. The
endovascular procedure of PTA was associated with the
lowest LOS in both groups, with LOS almost twice as long
for those patients undergoing open bypass surgery.
In summary, this paper is the ﬁrst to report on the
Australian hospital costs associated with inpatients with
PAD with or without DM undergoing a vascular surgical
procedure. The hospital cost of DM as a comorbid condition
in patients with PAD who underwent lower limb surgical
interventions is signiﬁcant. Patients with PADDM stayed
signiﬁcantly longer in hospital and accounted for greater
use of hospital resources than patients with PAD alone.
Factors that were found to predict increased LOS, apart
from DM, were performance of bypass surgery, perfor-
mance of amputation, CKD stage V, infection, and emer-
gency admission.
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